LIRALTAGENE AUTOLEUCEL
UNII 6NEK9A2UZ5

Substance Identification & Data

This profile provides standardized clinical and technical data for Liraltagene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 6NEK9A2UZ5.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

6NEK9A2UZ5

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LIRALTAGENE AUTOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C216001

National Cancer Institute reference terminology for clinical and research data.

INN ID

13378

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Liraltagene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LIRALTAGENE AUTOLEUCEL

Common Names & Synonyms

AUTOLOGOUS CD4+/CD8+ ENRICHED T LYMPHOCYTES DERIVED FROM LEUKAPHERESIS MATERIAL, TRANSDUCED WITH A NON-REPLICATING MURINE STEM CELL VIRUS (MSCV)-DERIVED GAMMA RETROVIRAL VECTOR, ENCODING CODON-OPTIMISED FOLLICLE-STIMULATING HORMONE (FSH) (SUBUNITS FSH.BETA. AND CG.ALPHA., LINKED BY A GLYCINE/SERINE SPACER), PRECEDED BY THE FSH.BETA. SIGNAL PEPTIDE, AND FUSED TO A CD8.ALPHA. HINGE AND TRANSMEMBRANE DOMAIN, A 4-1BB CO-STIMULATORY DOMAIN AND A CD3.ZETA. SIGNALLING DOMAIN, UNDER CONTROL OF THE MOLONEY MURINE LEUKEMIA VIRUS (MMLV) LTR PROMOTER. THE VECTOR ALSO HAS LONG TERMINAL REPEATS (LTRS) DERIVED FROM MSCV AND AN EXTENDED PACKAGING SIGNAL (.PSI.+) DERIVED FROM MMLV AND HAS A SPLICE ACCEPTOR SEQUENCE IMMEDIATELY UPSTREAM OF THE START CODON. A KOZAK SEQUENCE PRECEDES THE TRANSGENE.

LIRALTAGENE AUTOLEUCEL [INN]

External Clinical & Regulatory Resources

Previous UNII6NED3EZ9BK

Next UNII6NEX0L1V9U